Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
The present study provides the
2019-07-12
The present study provides the first evidence that the human uroepithelial cdc42 inhibitor in vitro respond directly, within 48h, to this carcinogen by promoting extensive vacuolation and DAPK expression. By using the TEM, ICC and Western blotting, we found that the arsenite-induced vacuoles were d
-
p Kip is a critical component of the cell cycle
2019-07-12
p27Kip1 is a critical component of the cell cycle machinery [15]. As an inhibitor of cyclin E-Cdk2, p27Kip1 plays a pivotal role in controlling cell proliferation, S-phase entry, and G1-phase exit during development and tumorigenesis [16]. p27Kip1 is predominantly regulated via posttranslational mod
-
CSN was initially identified based on the constitutitvely ph
2019-07-12
CSN was initially identified based on the constitutitvely photormophogenic (cop) mutants from Arabidopsis thaliana [48]. csn mutants are Cullin deneddylation-deficient, consequently accumulate neddylated Cullins, and arrest growth shortly after germination [49, 50, 51]. Weak csn mutants have defects
-
Paxilline what Compound A and Compound B
2019-07-12
Compound A and Compound B (Fig. 4) were found in our in vitro screening assays and have similar CRF1 receptor in vitro profiles (Table 1). When binding was investigated using [125I]-CRF in ex vivo assay, Compound A inhibited binding of [125I]-CRF both in the frontal cortex and the pituitary; however
-
The Czech Republic is a country with
2019-07-12
The Czech Republic is a country with increasing CDI incidence (1.1 cases per 10,000 patient bed-days in 2008–4.4 cases in 2011–2012 and 6.2 cases per 10,000 patient bed-days in 2012–2013) (Bauer et al., 2011, Davies et al., 2014) and relatively high rates of antibiotic resistant C. difficile strains
-
br Experimental br Results and discussion On
2019-07-12
Experimental Results and discussion On the basis of the information obtained from the studies on RHA/TiO2 nanocomposites, it (R)-baclofen is expected that this reagent can be used as a catalyst for the promotion of the organic reactions. So this reagent was used in the promotion of the conver
-
Ligand independent constitutively active variants have also
2019-07-12
Ligand-independent, constitutively active variants have also been found in receptors with associated tyrosine kinases. In approximately 60% of patients harboring inflammatory hepatocellular adenomas (IHCAs), these adenomas have been caused by small in-frame deletions in the cytokine-binding domain o
-
What is the predominant mechanism underlying the benefits
2019-07-11
What is the predominant mechanism underlying the benefits of udenafil, i.e. the vascular vs. myocardial effect? Lewis et al. suggested that the benefit of sildenafil in HFrEF would be derived from augmented RV systolic function that mainly results from pulmonary vasodilation, suggestive of the ‘vasc
-
Selective inhibitor of phosphodiesterase type PDE I
2019-07-11
Selective inhibitor of phosphodiesterase type 5 (PDE5I) is commonly used for ED treatment. PDE5I exhibits its vasodilatory effect by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), which relaxes the smooth muscle and allows increased blood flow for penile tumescence. Udenafil (D
-
The identification of CRF receptor
2019-07-11
The identification of CRF pi3k inhibitors subtypes has led to a number of studies addressing its functional properties. This paper examines the evidence for CRF1 and CRF2 mediation of fear and anxiety. Recent reviews discussing specific CRF receptor functions associated with other conditions includi
-
Early VL diagnosis makes it possible
2019-07-11
Early VL diagnosis makes it possible to formulate a quicker and more effective treatment against the disease, which could increase the possibility of a cure for the patients, as well as reduce the toxicity of the drugs (Coelho et al., 2009); however, conventional and molecular parasitological method
-
CGS 21680 HCl br Acknowledgements We thank Dr Tai
2019-07-11
Acknowledgements We thank Dr. Tai-Yuan Yu and Miss Chun-Ping Chang for helping with the drug/DNA sequence specificity study. We also thank the Chemical Synthesis Core and the Pathology Core Laboratory of IBMS for synthesizing SL-1 and for performing the pathology analysis, respectively, and the T
-
The use of recombinant ER
2019-07-11
The use of recombinant ERα and ERβ binding assays offers a relatively inexpensive, rapid technique for screening compounds for potential direct Esomeprazole Sodium molecular receptor modulatory activity and understanding the mechanisms of existing herbal medicines. For background on the protein prod
-
In contrast DGAT does not interact with mitochondria and LDs
2019-07-11
In contrast, DGAT1 does not interact with mitochondria and LDs but can form dimers and tetramers [76]. It has been reported that the hydrophilic N-terminal region of DGAT1, which is not required for acyltransferase activity, has the roles in regulating enzyme activity and the formation of dimers and
-
Emi protein consists of an N terminal regulatory region and
2019-07-11
Emi2 protein consists of an N-terminal regulatory region and a C-terminal functional region. The C-terminal region contains a destruction box (D-box), which likely competes with APC/C substrates (including cyclin B) for APC/C binding, and a zinc-binding region (ZBR), which somehow inhibits APC/C ubi
15280 records 977/1019 page Previous Next First page 上5页 976977978979980 下5页 Last page